On October 17, 2005, the Food and Drug Administration approved an application to allow use of the pediatric/adolescent formulation of Havrix® (hepatitis A vaccine, inactivated) (GlaxoSmithKline Biologicals, Rixensart, Belgium) for persons aged 1--18 years. Previously, pediatric use of Havrix was approved for use in persons aged 2--18 years.

Recommendation Americas United States of America Hepatitis A